What Do Recent Insider Sales at Immunome (IMNM) Signal
Recent insider sales at Immunome (IMNM) by the Chief Scientific Officer and Chief Financial Officer, totaling over $1.6 million, have prompted investor scrutiny despite the company's 268.3% stock surge in the past year. While Immunome boasts a promising pipeline with antibody-drug conjugates (ADCs) in oncology and COVID-19 therapeutics, it remains unprofitable with a high Price/Sales ratio, making its valuation highly speculative and dependent on future clinical successes. Investors are advised to weigh the substantial growth potential against significant risks, including clinical trial uncertainties, ongoing capital requirements leading to dilution, intense competition, and the cautionary signal from executive divestments.
Immunome Inc stock (US45254C1062): biotech investor attention after oncology pipeline update
Immunome Inc is gaining investor attention following recent oncology pipeline updates and investor presentations, highlighting its progress in antibody-based cancer therapies. The company operates in the highly competitive biotechnology sector, leveraging its memory B cell platform for drug discovery. Immunome's business model relies on R&D, collaborations, and capital markets, with its financial performance heavily influenced by R&D spending and potential milestone payments rather than product sales.
Immunome director Bienaime buys $103,500 in company stock By Investing.com
Immunome Inc. director Jean Jacques Bienaime purchased 5,000 shares of the company's common stock for a total of $103,500 on May 15, 2026. This transaction increased his direct holdings to 43,415 shares. The purchase occurred after a 12% stock decline in the past week, although shares have surged 148% over the last year, and the stock trades near its Fair Value according to InvestingPro.
Insider Buying: Jean Bienaime Acquires 5,000 Shares of Immunome Inc (IMNM)
Jean Bienaime, a Director at Immunome Inc (IMNM), recently purchased 5,000 shares, increasing his total holdings to 43,415 shares. This transaction is part of a trend revealing 8 insider buys versus 4 insider sells at Immunome over the past year. With the stock trading at $20.70 and a GF Value of $2.05, the company appears to be significantly overvalued according to GuruFocus's intrinsic value estimate.
Director Bienaime adds 5,000 Immunome (IMNM) shares in open-market buy
Immunome Inc. director Jean Jacques Bienaime purchased an additional 5,000 shares of the company's common stock on May 15, 2026, through an open-market transaction. The shares were bought at a weighted average price of $20.70 per share, ranging from $20.645 to $20.72. This transaction increased Bienaime's direct holdings to 43,415 shares, signifying a positive sentiment regarding the company.
Immunome director Bienaime buys $103,500 in company stock
Immunome director Jean Jacques Bienaime purchased 5,000 shares of Immunome Inc. (NASDAQ:IMNM) common stock for $103,500 on May 15, 2026. This transaction increased his direct holdings to 43,415 shares, following a week where the stock declined by 12% but surged 148% over the past year. The company recently submitted a New Drug Application for varegacestat, a treatment for desmoid tumors, supported by positive Phase 3 trial data.
Immunome Inc stock (US45254C1062): oncology deal momentum keeps biotech in focus
Immunome Inc (IMNM) is gaining investor attention due to a significant oncology antibody deal with Zentalis Pharmaceuticals and advancements in its antibody programs. The US biotech company focuses on developing antibody-based therapies for oncology, leveraging its discovery platforms and balancing internal pipeline progression with collaborations to secure funding and future revenue streams. While early-stage, the company's Nasdaq listing and focus on cancer targets make it relevant for US biotech investors seeking exposure to oncology innovation, despite the inherent high risks of clinical development and funding dependence.
Immunome Inc stock (US45254C1062): oncology deal momentum keeps investors watching
Immunome Inc, a clinical-stage biotechnology company, is gaining investor attention due to recent deals and pipeline updates in oncology and antibody discovery. The company's business model focuses on developing antibody-based therapies for cancer and immune-related diseases, relying on collaborations with larger pharmaceutical companies for late-stage development and commercialization. Immunome's strategy involves discovering naturally occurring antibodies to design drug candidates, with revenue primarily derived from collaboration agreements, upfront payments, research funding, and potential milestones rather than product sales.
Immunome (NASDAQ:IMNM) Stock Rating Upgraded by Wall Street Zen
Wall Street Zen has upgraded Immunome (NASDAQ:IMNM) from a "sell" to a "hold" rating, though other analysts largely maintain a "Moderate Buy" consensus with an average price target of $32.82. Despite beating quarterly earnings expectations with a loss of ($0.48) per share against an estimated ($0.60), analysts still anticipate unprofitability for the year. The stock traded down 5.2% to $20.88, while key insiders have recently sold shares, even as institutional investors hold a significant stake.
Redmile Group and Jeremy C. Green disclose 4.9% stake in Immunome (IMNM)
Redmile Group, LLC and Jeremy C. Green have disclosed a 4.9% beneficial stake in Immunome Inc. (IMNM), totaling 5,558,885 shares. This stake, held through Redmile-managed investment vehicles, is reported in an amended Schedule 13G/A filing. The ownership percentage is based on 113,133,199 shares outstanding as of February 27, 2026, and the filing indicates shared voting and dispositive power without direct beneficial ownership explicitly claimed by Redmile or Mr. Green.
Point72 and Steven A. Cohen report 0% ownership in Immunome (IMNM)
Point72 Asset Management, Point72 Capital Advisors Inc., and Steven A. Cohen have filed an amended Schedule 13G/A for Immunome (IMNM), reporting 0% beneficial ownership of the company's common stock as of March 31, 2026. This disclosure indicates that they hold no voting or dispositive power over any Immunome shares, representing a factual ownership update rather than an investment action. The filing confirms that their group no longer maintains a reportable stake in the company.
Sirenia Capital reports 6.1% stake in Immunome (NASDAQ: IMNM) via Schedule 13G
Sirenia Capital Management and Alex Silverstein have reported a 6.1% beneficial ownership stake in Immunome Inc. (NASDAQ: IMNM), totaling 6,895,000 shares. This disclosure was made via a joint Schedule 13G filing, indicating a passive investment. The percentage is based on 113,133,199 shares outstanding as of February 27, 2026, and the filing specifies shared voting and dispositive power.
Piper Sandler Maintains Immunome(IMNM.US) With Buy Rating, Maintains Target Price $33
Piper Sandler has reiterated its Buy rating for Immunome (IMNM.US), maintaining a target price of $33. This indicates a continued positive outlook on the company's stock performance from the analyst firm.
Analyst Reiterates Buy on Immunome, Maintains $40 Price Target on Varegacestat Progress and Pipeline Upside
H.C. Wainwright analyst Andres Y. Maldonado has reiterated a Buy rating on Immunome, maintaining a $40 price target. This decision is based on the strong progress of varegacestat through its Phase 3 trials and regulatory filings, along with the promising potential of Immunome's broader pipeline, including the newly initiated Phase 1 program for IM-3050 and the maturing ADC franchise. Maldonado highlights the company's sustained innovation and expansion capabilities as key drivers for this positive outlook.
Immunome Reports First Quarter 2026 Financial Results and Provides Business Update
Immunome, Inc. announced its financial results for the first quarter of 2026, highlighting significant progress in its targeted oncology pipeline. Key developments include the submission of a New Drug Application (NDA) for varegacestat for desmoid tumors, detailed Phase 3 RINGSIDE data selected for presentation at ASCO, and advancements in its antibody-drug conjugate (ADC) programs with IM-1021 and IM-1617. The company reported a cash and cash equivalents total of $582.7 million, funding operations into 2028, and a net loss of $53.8 million for the quarter.
Immunome 1Q Loss/Shr 48c >IMNM
Immunome reported a first-quarter loss per share of 48 cents, which met analyst expectations. The company also announced that its cash, cash equivalents, and marketable securities totaled $119.5 million at the end of the quarter.
Immunome (NASDAQ: IMNM) files varegacestat NDA while Q1 loss grows on higher R&D
Immunome Inc. (NASDAQ: IMNM) reported a wider net loss of $53.8 million in Q1 2026, compared to $41.6 million in Q1 2025, primarily due to increased research and development (R&D) expenses of $46.4 million. Despite the loss, the company ended the quarter with a strong cash position of $582.7 million, which is expected to fund operations for at least 12 months. Key pipeline advancements include the submission of a New Drug Application (NDA) for varegacestat for desmoid tumors and progress in several other oncology programs.
Immunome Inc stock (US45254C1062): NDA submission for varegacestat in desmoid tumors
Immunome Inc has submitted a New Drug Application (NDA) to the FDA for varegacestat, a gamma-secretase inhibitor, to treat desmoid tumors, a rare soft tissue cancer. This submission is a significant regulatory milestone for the NASDAQ-listed biotech company, which specializes in targeted oncology therapies. Varegacestat targets Notch signaling pathways and, if approved, could achieve first-in-class status for this orphan indication.
Immunome Inc reports results for the quarter ended March 31 - Earnings Summary
Immunome Inc has released its earnings summary for the quarter that concluded on March 31. The report contains the company's financial results for the specified period. Further details are available through a login or free account creation.
Immunome Inc. 1Q 2026: Revenue $0 EPS $(0.48) — 10-Q Summary
Immunome Inc. (IMNM) reported its first-quarter 2026 financial results, showing revenue of $0 and a net loss attributable to stockholders of $53.8 million, or $(0.48) diluted loss per share. This compares to $2.9 million in revenue and a $(0.52) loss per share in Q1 2025, with the previous year's revenue including collaboration with AbbVie. The company highlighted progress in its pipeline, including an NDA submission for varegacestat and advancing several clinical and preclinical assets.
Cancer NDA and wider Q1 2026 loss at Immunome (IMNM) with strong Phase 3 data
Immunome reported a wider net loss of $53.8 million in Q1 2026 but highlighted significant progress in its oncology pipeline, including the submission of a New Drug Application (NDA) for varegacestat for desmoid tumors supported by strong Phase 3 data. The company also advanced several antibody-drug conjugate programs and maintains a robust cash position of $582.7 million, expected to fund operations into 2028. This update signals continued investment in research and development despite increased quarterly losses, focusing on significant regulatory and clinical milestones.
Immunome Reports First Quarter 2026 Financial Results and Provides Business Update
Immunome, Inc. announced its financial results for the first quarter of 2026, highlighting key advancements in its oncology pipeline. The company submitted a New Drug Application (NDA) for varegacestat for desmoid tumors and plans a European submission, with detailed Phase 3 RINGSIDE data selected for oral presentation at the ASCO Annual Meeting. Immunome also provided updates on its ADC programs, including ongoing Phase 1 studies for IM-1021 and IM-1617, and reported a cash position of $582.7 million expected to fund operations into 2028.
Nan Fung Trinity HK Ltd. Grows Position in Immunome, Inc. $IMNM
Nan Fung Trinity HK Ltd. increased its stake in Immunome, Inc. (NASDAQ:IMNM) by 20.7% in the fourth quarter, now holding 714,553 shares valued at approximately $15.35 million. Other institutional investors also raised their positions, leading to hedge funds and institutions owning 44.58% of Immunome's stock. Despite analyst consensus for a "Moderate Buy" and an average price target of $33.45, the company reported a wider-than-expected quarterly loss and saw significant insider selling.
Immunome, Inc. (IMNM) Reports Submission of an NDA for Varegacestat in Desmoid Tumors
Immunome, Inc. (NASDAQ:IMNM) has submitted a New Drug Application (NDA) to the FDA for varegacestat to treat desmoid tumors, based on positive Phase 3 RINGSIDE trial data. The trial demonstrated an 84% reduction in the risk of disease progression or death and a 56% confirmed response rate compared to placebo. Varegacestat also showed an 83% median tumor shrinkage and manageable side effects.
Assessing Immunome (IMNM) Valuation After Varegacestat NDA And Phase 3 Desmoid Tumor Success
Immunome (IMNM) recently filed a New Drug Application (NDA) for varegacestat, backed by a successful Phase 3 study, yet its shares trade at a significant discount to analyst targets and an intrinsic value estimate of $180.09. Despite a 4x Price-to-Book ratio, which is above the industry average, a Discounted Cash Flow model indicates the stock is undervalued, though clinical and funding risks persist. The article suggests investors consider both the strong returns and potential risks when evaluating IMNM.
Immunome (IMNM) moves 13.3% higher: Will this strength last?
The article notes that Immunome (IMNM) stock increased by 13.3%. It poses the question of whether this upward trend will continue, suggesting an analysis of the stock's recent performance is relevant for investors.
10 Best Biotech Stocks to Invest In According to Billionaire Steve Cohen
The article highlights Immumone, Inc. (NASDAQ: IMNM) as one of the best biotech stocks favored by billionaire Steve Cohen's Point72 Asset Management. It details Immunome's successful Phase 3 RINGSIDE trial for varegacestat, showing significant improvements in progression-free survival and tumor size reduction for desmoid tumors. The company has filed a new drug application with the FDA based on these positive results.
Immunome (IMNM) moves 13.3% higher: Will this strength last?
This article discusses the recent 13.3% increase in Immunome (IMNM) stock. It raises the question of whether this positive momentum will continue. The content provided is minimal, focusing solely on the stock's performance.
Assessing Immunome (IMNM) Valuation As Premium P/B And DCF Signals Point In Different Directions
Immunome (IMNM) is facing conflicting valuation signals, with its Price-to-Book (P/B) ratio of 4x suggesting overvaluation compared to the broader biotech industry, while Simply Wall St's Discounted Cash Flow (DCF) model indicates a significant undervaluation at $180.09 per share against its current price of $22.19. The article highlights the importance of analyzing underlying data to reconcile these disparate signals and consider both potential upsides and risks for investors.
Assessing Immunome (IMNM) Valuation As Premium P/B And DCF Signals Point In Different Directions
Immunome (IMNM) is currently trading around US$22.19 with a market value near US$2.64 billion, showing strong long-term returns but recent declines. The stock's Price-to-Book (P/B) ratio of 4x is a premium to the US biotech industry average, suggesting it may be overvalued based on this metric. However, Simply Wall St's Discounted Cash Flow (DCF) model estimates a fair value of $180.09 per share, indicating a significant potential upside despite the company's current losses and small revenue base.
Immunome earnings up next: Cash burn eyed after NDA filing
Immunome Inc. is scheduled to release its first-quarter results, with analysts and investors focused on the company's cash burn following the recent New Drug Application (NDA) submission for its lead drug candidate, varegacestat. Despite a consensus strong buy rating from analysts and significant stock appreciation, the clinical-stage biotech company is not expected to achieve profitability soon, making its burn rate and regulatory updates crucial for investors. The company recently completed a $400 million equity raise to support its operations and pipeline development.
Immunome earnings up next: Cash burn eyed after NDA filing
Immunome Inc. is scheduled to report first-quarter results, with analysts expecting a loss of 55 cents per share on revenue of $200,000. The report follows the company's recent New Drug Application submission for varegacestat, an investigational treatment for desmoid tumors. Investors will focus on the company's cash burn rates and operating expenses, especially given its lack of commercial revenue and a recent $400 million equity raise.
How Immunome’s (IMNM) Varegacestat NDA and Phase 3 Data Could Reshape Its Desmoid Tumor Story
Immunome has submitted a New Drug Application (NDA) for varegacestat, an oral gamma secretase inhibitor for desmoid tumors, supported by strong Phase 3 trial data. This submission is a significant near-term catalyst, though the stock's high valuation and recent dilution present risks. Investor sentiment surrounding Immunome is highly sensitive to new information, given the wide range of fair value estimates.
Immunome earnings up next: Cash burn eyed after NDA filing
Immunome Inc. is set to report first-quarter results, with analysts expecting a narrower loss per share and minimal revenue. Investors will be closely watching the company's cash burn following its recent NDA submission for varegacestat and a $400 million equity raise, given the absence of commercial revenue and ongoing operating losses. The stock has strong "strong buy" ratings from analysts, who anticipate 52% upside from the current price.
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - May 5, 2026
Immunome, Inc. announced that its Compensation Committee granted inducement awards of non-statutory stock options to 19 new employees on May 1, 2026, totaling 450,000 shares of common stock. These options, granted under Nasdaq Listing Rule 5635(c)(4) as an inducement for employment, have an exercise price of $22.73 and vest over four years. The company is a clinical-stage targeted oncology company developing various cancer therapies.
How Immunome’s (IMNM) Varegacestat NDA and Phase 3 Data Could Reshape Its Desmoid Tumor Story
Immunome has submitted a New Drug Application (NDA) to the FDA for varegacestat, an oral treatment for desmoid tumors, supported by positive Phase 3 RINGSIDE trial data. This submission is a significant near-term catalyst for the company, as the trial represents the largest randomized study in this rare tumor type. While the stock has seen a large return and trades at a premium, the investment narrative hinges on varegacestat's commercial success amidst existing financial risks and varying analyst expectations.
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Immunome announced inducement grants of stock options and restricted stock units (RSUs) to three new employees. These grants were made under Nasdaq Listing Rule 5635(c)(4) as a material inducement for their employment with the company. The options have an exercise price equal to the closing price of Immunome's common stock on May 1, 2026, and vest over four years, while the RSUs vest over three years.
How Immunome’s (IMNM) Varegacestat NDA and Phase 3 Data Could Reshape Its Desmoid Tumor Story
Immunome has submitted a New Drug Application (NDA) to the FDA for varegacestat, an oral treatment for desmoid tumors, supported by positive Phase 3 trial results. This submission represents a key near-term catalyst for the company, though the stock has already seen significant returns and trades at a premium. The market harbors varied expectations for Immunome's valuation, and investors need to weigh the potential for a successful product against existing financial risks and the uncertainty of FDA approval and market uptake.
Analysts Have Conflicting Sentiments on These Healthcare Companies: Amgen (AMGN), Immunome (IMNM) and Resmed (RMD)
This article analyzes recent analyst ratings for three healthcare companies: Amgen (AMGN), Immunome (IMNM), and Resmed (RMD). Amgen received a Moderate Buy consensus with a target price suggesting a 7.0% upside. Immunome garnered a Strong Buy consensus, indicating a significant 54.0% upside. Resmed, however, received a Moderate Buy consensus but with a mixed sentiment from recent analyst actions, including a downgrade.
Lake Street Maintains Immunome(IMNM.US) With Buy Rating, Maintains Target Price $30
Lake Street has reaffirmed its Buy rating for Immunome (IMNM.US) and maintained its price target of $30. This decision indicates continued confidence in the company's financial prospects and stock performance from the analytical firm.
Universal Beteiligungs und Servicegesellschaft mbH Acquires New Position in Immunome, Inc. $IMNM
Universal Beteiligungs und Servicegesellschaft mbH has acquired a new stake of 170,002 shares in Immunome (NASDAQ:IMNM), valued at approximately $3.65 million. This coincides with insider selling, as CFO Max Rosett and insider Jack Higgins sold shares totaling over $1.6 million, though insiders still own 7.69% of the company. Immunome currently has a "Moderate Buy" consensus rating from analysts, with a target price of $33.45, despite recently missing EPS estimates and trading near $22.95.
Immunome Announces Submission of New Drug Application to U.S. FDA for Varegacestat for the Treatment of Adults with Desmoid Tumors
Immunome has submitted a New Drug Application (NDA) to the U.S. FDA for varegacestat, an oral gamma secretase inhibitor, for adult patients with desmoid tumors. This submission is supported by positive Phase 3 RINGSIDE trial results, which showed significant improvement in progression-free survival and objective response rates compared to placebo. The data will also be presented at the 2026 ASCO Annual Meeting.
Immunome announces submission of NDA for varegacestat in desmoid tumors
Immunome (IMNM) has submitted a New Drug Application (NDA) to the U.S. FDA for varegacestat, an oral gamma secretase inhibitor, to treat adults with desmoid tumors. The submission is based on positive results from the Phase 3 RINGSIDE trial, which showed varegacestat significantly improved progression-free survival, objective response rates, and tumor volume reduction compared to placebo, with a manageable safety profile.
Immunome Announces Submission of New Drug Application to U.S. FDA for Varegacestat for the Treatment of Adults with Desmoid Tumors
Immunome, Inc. announced the submission of a New Drug Application (NDA) to the U.S. FDA for varegacestat, an oral gamma secretase inhibitor, for adult patients with desmoid tumors. The submission is backed by strong positive results from the Phase 3 RINGSIDE trial, which demonstrated a significant improvement in progression-free survival and objective response rates compared to placebo. Varegacestat was also generally well-tolerated, and detailed data from the trial will be presented at the 2026 ASCO Annual Meeting.
IMNM - Immunome Inc Stock Price and Quote
This page provides a comprehensive overview of Immunome Inc. (IMNM) stock, including its current price, financial metrics, analyst ratings, and recent news. It details key financial figures like market cap and P/E ratio, lists insider trading activities, and summarizes news events such as NDA submissions to the FDA and investor conference presentations.
Immunome prices $400M stock offering at $21.50 a share
Immunome has priced a public offering of 18,604,651 shares of its common stock at $21.50 per share, aiming to raise approximately $400 million before deductions. This offering includes a 30-day option for underwriters to purchase up to 2,790,697 additional shares. The offering is expected to close around April 30, 2026.
The Bull Case For Immunome (IMNM) Could Change Following Varegacestat’s ASCO 2026 Spotlight And NDA Timeline – Learn Why
Immunome (IMNM) recently announced that data for its drug varegacestat, used for desmoid tumor patients, will be presented at the 2026 ASCO Annual Meeting, with a New Drug Application (NDA) to the US FDA planned for Q2 2026. This development could significantly impact Immunome's investment narrative, as the company faces ongoing losses and relies on the successful approval and uptake of varegacestat to anchor its oncology platform. Despite the positive news, the article suggests Immunome's shares might still be trading above fair value, indicating potential downside for new shareholders.
The Bull Case For Immunome (IMNM) Could Change Following Varegacestat’s ASCO 2026 Spotlight And NDA Timeline – Learn Why
Immunome, Inc. announced that data from its Phase 3 trial of varegacestat for desmoid tumors will be presented at ASCO 2026, with an NDA filing planned for Q2 2026. This news strengthens the investment narrative for Immunome, focusing on successful regulatory approval and commercialization. However, the company faces ongoing cash burn and the stock's fair value remains a point of wide disagreement among analysts.
[ARS] Immunome Inc. SEC Filing
This article reports on an ARS SEC filing by Immunome Inc. (IMNM), noting its low impact and neutral sentiment. The filing, dated April 24, 2026, concerns Immunome Inc. and is available as a PDF document. The article also provides an overview of Immunome's market performance, recent news, and other SEC filings.
The Bull Case For Immunome (IMNM) Could Change Following Varegacestat’s ASCO 2026 Spotlight And NDA Timeline – Learn Why
Immunome, Inc. announced that data from its Phase 3 trial of varegacestat for desmoid tumor patients will be presented at the 2026 ASCO Annual Meeting, with a New Drug Application to the US FDA planned for Q2 2026. This development could significantly impact Immunome's investment narrative, as the company's financial success hinges on this drug's approval and market adoption. Despite share price fluctuations and ongoing losses, the ASCO presentation and NDA submission are key catalysts for the company.
